Dr Grant Stewart
Personal home page:
PubMed journal articles - click here
Dr Grant Stewart is pleased to consider applications from prospective PhD students.
Grant Stewart is an academic urological surgeon at Cambridge University with clinical and research expertise in kidney cancer. Grant has a specific interest in optimising management of patients with initially localised renal cancer, an area of great need within the disease. In order to make practice changing developments in this area Grant Stewart has developed a range of interlinked clinical trials and translational research which are all underpinned by clinical excellence in managing renal cancer at Addenbrooke’s Hospital, Cambridge. To deliver on the above goals, Grant coordinates the Cambridge Renal Cancer Collaboration (CamRenCan) a group of 40 clinicians, translational researchers and basic scientists across the Cambridge Biomedical Campus with a shared interest in renal cancer research.
Grant Stewart moved to Cambridge in October 2015 from a post as Senior Lecturer in Urological Surgery at the University of Edinburgh where he led the Edinburgh Urological Cancer Group. Grant developed and co-directs the Scottish Collaboration On Translational Research into Renal Cell Cancer (SCOTRRCC), a Scotland-wide kidney cancer biorepository of 1200 patients with high quality clinical data linkage.
Mr Stewart chairs the Renal Cancer Surgical Subgroup of the National Cancer Research Institute Bladder and Renal Cancer Clinical Studies Group, Co-Chair of the Renal Cross Channel Group, sits on the Medical Advisory Board for Cambridge Medical Robotics, is Chair of the Scientific and Education Committee of The Urology Foundation and is CI/PI for several renal cancer clinical trials. Grant is an Honorary Senior Lecturer at the University of Edinburgh where he is Programme Director of the Urology ChM.
kidney cancer; renal cell cancer; RCC; adjuvant; neoadjuvant; window-of-opportunity; clinical trials; heterogeneity; localised disease; minimal residual disease
Symplectic Elements feed provided by Research Information, University of Cambridge
A.L.R. Lubbock, G.D. Stewart (joint 1st author), F.C. O’Mahony, A. Laird, P. Mullen, M. O’Donnell, T. Powles, D.J. Harrison, I.M. Overton. Overcoming intratumoural heterogeneity for reproducible molecular risk stratification: a case study in advanced kidney cancer. BMC Medicine. 2017. 26;15(1):118.
S.H. Rossi, R. Hsu, C. Blick, V. Goh, P. Nathan, D. Nicol, S. Fleming, M. Sweeting, E.C.F. Wilson, G.D. Stewart. A meta-analysis of the prevalence of renal cancer detected by abdominal ultrasonography in asymptomatic individuals. British Journal of Surgery. 2017; 104: 648–659.
C. Blick, A. Ritchie, T. Eisen, G.D. Stewart. Improving outcomes in high-risk, nonmetastatic renal cancer: new data and ongoing trials. Nature Reviews Urology. 2017 Aug 1. doi: 10.1038/nrurol.2017.12
G.D. Stewart, F.C. O'Mahony, A. Laird, L. Eory, A.L.R. Lubbock, A. Mackay, J. Nanda, M. O'Donnell, P. Mullen, S.A. McNeill, A.C.P. Riddick, D. Berney, A. Bex, M. Aitchison, I.M. Overton, D.J. Harrison, T. Powles. Sunitinib treatment exacerbates intratumoral heterogeneity in metastatic renal cancer. Clinical Cancer Research. 2015; 21(18): 4212-23.
G.D. Stewart, F.C. O'Mahony, A. Laird, S. Rashid, S.A. Martin, L. Eory, A.L.R. Lubbock, J. Nanda, M. O'Donnell, A. Mackay, P. Mullen, S.A. McNeill, A.C.P. Riddick, M. Aitchison, D. Berney, A. Bex, I.M. Overton, D.J. Harrison, T. Powles. Carbonic anhydrase 9 expression increases with VEGF targeted therapy and is predictive of outcome in metastatic clear cell renal cancer. European Urology. 2014; 66: 956-963.
K. Sharpe, G.D. Stewart (joint 1st author), A. Mackay, C. Van Neste, C. Rofe, D.M. Berney, I. Kayani, A. Bex, E. Wan, F. O'Mahony, M. O'Donnell, S. Chowdhury, R. Doshi, C. Ho Yen, M. Gerlinger, D. Baker, N.R. Smith, B.R. Davies, A. Sahdev, E. Boleti, T. de Meyer, W. Van Criekinge, L. Beltran, Y-J. Lu, D. Harrison, A.R. Reynolds, T. Powles. The effect of VEGF targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancer. Clinical Cancer Research. 2013; 19: 6924-6934.
A. Laird, F.C. O'Mahony, J. Nanda, A.C.P. Riddick, M. O'Donnell, D.J. Harrison, G.D. Stewart. Differential expression of prognostic proteomic markers proteins in primary tumour, venous tumour thrombus and metastatic renal cell cancer tissue and correlation with patient outcome. PLoS ONE. 2013; 8 (4): e60483.
T. Powles, I. Kayani, K. Sharpe, L. Lim, J. Peters, G.D. Stewart, D. Berney, A. Sahdev, S. Chowdhury, E. Boleti, J. Shamash, A.R. Reynolds, R. Jones, C. Blank, J. Haanen, A. Bex. A prospective evaluation of VEGF targeted treatment cessation in metastatic clear cell renal cancer. Annals of Oncology. 2013; 24 (8): 2098-103.
G.D Stewart, L. Van Neste, P. Delvenne, P. Delrée, A. Delga, S.A. McNeill, M. O'Donnell, J. Clark, W. Van Criekinge, J. Bigley, D.J. Harrison. Clinical Utility of an Epigenetic Assay to Detect Occult Prostate Cancer in Histopathologically Negative Biopsies: Results of the MATLOC Study. Journal of Urology. 2013; 189 (3): 1110-1116.
G.D. Stewart, F.C. O'Mahony, T. Powles, A.C.P. Riddick, D.J. Harrison, D. Faratian. What can molecular pathology contribute to the management of renal cell carcinoma? Nature Reviews Urology. 2011; 8: 255-265.
B.M. Wieland, G.D. Stewart, R.J.E. Skipworth, K. Sangster, K.C.H. Fearon, J.A. Ross, T.J. Reiman, J. Easaw, M. Mourtzakis, V. Kumar, B.J. Pak, K. Calder, G. Filippatos, D.T. Kremastinos, M. Palcic, V.E. Baracos. Is there a human homolog to the murine proteolysis?inducing factor? Clinical Cancer Research. 2007; 13 (17): 4984-4992.